HIV-1 Gag Gene Mutations and Treatment Outcomes
Author Information
Author(s): Ghosn Jade, Delaugerre Constance, Flandre Philippe, Galimand Julie, Cohen-Codar Isabelle, Raffi François, Delfraissy Jean-François, Rouzioux Christine, Chaix Marie-Laure
Primary Institution: Paris Descartes University, EA 3620, Necker University Hospital, Paris, France
Hypothesis
Do mutations in the Gag gene affect the efficacy of a first-line Lopinavir/Ritonavir monotherapy in HIV-1 patients?
Conclusion
Pre-therapy mutations in the Gag cleavage site sequence were significantly associated with the virological outcome of a first-line Lopinavir/Ritonavir single drug regimen.
Supporting Evidence
- 81 out of 82 isolates carried at least one substitution in the Gag cleavage site.
- Non-B subtype isolates were significantly more likely to harbor mutations in Gag cleavage sites than B subtype isolates.
- The presence of more than two substitutions in the p2/NC site at baseline significantly predicted virological failure.
Takeaway
This study looked at how changes in a part of the HIV virus called Gag might affect how well a specific treatment works. It found that some changes can make the treatment less effective.
Methodology
Patients were randomly assigned to receive first-line Lopinavir/Ritonavir monotherapy or a combination therapy, and their Gag gene sequences were analyzed for mutations.
Potential Biases
Potential bias due to the study's focus on specific subtypes and the adherence levels of participants.
Limitations
The study may not be generalizable to all HIV-1 subtypes, as it focused on non-B subtypes and their specific mutations.
Participant Demographics
Patients were antiretroviral-naïve HIV-infected individuals with a mix of B and non-B HIV-1 subtypes.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website